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Purpose. We investigated whether NS-RP increased risk of PSA failure and whether PSA should be included as a selection
criterion for NS. Methods. We evaluated 357 consecutive men with screen-detected PC who underwent open RP without adjuvant
radiotherapy between 9/11/2001 and 12/30/2008. Criteria for NS included Gleason score ≤3 + 4, percentage of positive biopsies
(PPB) ≤50%, percentage of core involvement ≤50%, nonapical location, no perineural invasion, and no palpable disease on pre-
or intraoperative exam but did not include a PSA threshold. Cox multivariable regression assessed whether increasing PSA or
unilateral- or bilateral-NS versus non-NS-RP was associated with PSA failure adjusting for prognostic factors. Results.A ft e ra
median follow-up of 3.96 years, 34 men sustained PSA failure (9.5%). Increasing PSA was significantly associated with increased
risk of PSA failure in the interaction model (adjusted hazard ratio (AHR): 1.09 [95% CI: 1.03–1.16]; 𝑃 = 0.005), whereas unilateral
(AHR: 1.24 [95% CI: 0.36–4.34]; 𝑃 = 0.73) or bilateral NS (AHR: 0.41 [95% CI: 0.06–2.59]; 𝑃 = 0.34)v e r s u sn o n - N SR Pw a sn o t .
Conclusion. NS-RP in a screened cohort did not increase risk of PSA failure using NS criteria not including PSA.
1. Introduction
Nerve-sparing (NS) radical prostatectomy (RP) was intro-
d u c e di n1 9 8 4b yD r .P a t r i c kW a l s ha sam e a n so fp r e s e r v -
ing potency and maintaining patient reported health related
quality of life following NS RP [1, 2]. This procedure involves
preservation of the neurovascular bundles (NVB), which
t r a v e ld o r s o l a t e r a lt ot h ep r o s t a t ea n da r eb e l i e v e dt os u p p l y
neurophysiologic control of erectile tissue [3]. NS RP has
been found to correlate with early return of urinary conti-
nence when applied in a risk-stratified approach [4], which
is another potential benefit of this approach.
Since that time, the procedure has been widely used,
with rates of patient reported postoperative potency ranging
from 21 to 89.7% after RP [5–11]. Despite the wide adoption
of NS RP, prospective randomized assessment of prostate
cancer control outcomes with or without NS is lacking. Some
have raised the concern that this procedure may place select
patientswithlargetumorburdenatincreasedriskofpost-RP
prostate-specific antigen (PSA) failure by increasing the risk
of positive surgical margins due to the close proximity of the
NVBs to the posterolateral aspect of the prostatic fascia [12–
14]. However, this concern has been debated [12, 15, 16].
Different investigators have attempted to define tumor
factors believed to optimize selection for NS to thereby
reduce the risk of a positive margin [12, 17, 18]. Earlier series
from the Washington University Medical Center describe
ideal candidates for NS RP as young patients with clinical
stage not exceeding T2 and well-differentiated tumors [18].
An algorithm from New York University (NYU) reserves
NS RP for patients with Gleason 6 or less tumors with per-
centage of positive biopsies (PPB) less than 50% or no
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perineural invasion (PNI), Gleason 7 tumors with PPB less
than 30% and no PNI, and Gleason 8 to 10 tumors with
PPB less than 10% and no PNI [17]. At the University of
Miami,Florida,similarcriteriaincludepreoperativepotency,
desire to maintain potency, biopsies with tumor on one side
only, T2b disease or less, intraoperative absence of palpable
indurationorperiprostaticfibrosis,Gleasonscoreof7orless,
PSA of 10ng/mL or less, and nonapical location of tumor
[12, 16].
At the Brigham and Women’s Hospital, criteria for NS by
side included Gleason score 3 + 4 or less, PPB and percent-
a g eo fc o r ei n v o l v e m e n t5 0 %o rl e s s ,n o n a p i c a ll o c a t i o n ,a n d
no perineural invasion or palpable disease on pre- or intra-
operative exam but did not include a maximum PSA value.
Therefore using these criteria as the basis for NS or not, the
currentstudywasdesignedtoinvestigatewhetheranincreas-
ing PSA level and whether unilateral (UNS) or bilateral
(BNS) versus non-NS RP were associated with an increased
risk of PSA failure adjusting for known predictors for PSA
recurrence in men who did not undergo adjuvant radiation
therapy.
2. Patients and Methods
2.1.PatientPopulationandTreatment. Weidentified357con-
secutively treated men with screen-detected biopsy proven
prostate cancer (PC) who underwent an open radical prosta-
tectomy by a single urologic oncologist between 9/11/2001
and 12/30/2008 at a single academic center. Determination
of the use of bilateral and unilateral NS was judged on each
s i d es e p a r a t e l ya n dw a sb a s e do nt h ep r e s e n c eo fG l e a s o n
score 3 + 4 or less, PPB and percentage of core involvement
50%orless,nonapicallocation,andnoperineuralinvasionor
palpable disease on pre- or intraoperative exam but did not
include a maximum PSA value.
2.2. Pathologic Processing of the RP Specimen. RP pathologic
specimens were step-sectioned and reviewed by an expert
genitourinary pathologist as previously described [19]. The
apical and basal margins were amputated to a thickness of
5mm and sectioned at 3mm intervals parasagittally or per-
pendicular to the initial transverse incision. The base of the
seminal vesicles was amputated and the basal cross-section
submitted. The prostate was sectioned as thinly as possible
perpendicularly to the long axis (apical to basal) of the gland,
typically at 3mm intervals, with most specimens requiring
four to seven cross-sections. For each cross-section, a single
sectioneachoftherigh tandleftposteriorregionwassubmit-
ted, with most cases entirely submitting the posterior zone.
Finally, at least one section of the mid-anterior prostate was
also submitted, although frequently more than one section
was submitted for histology analysis.
Evidence of extraprostatic disease including seminal
vesicle invasion (SVI), extracapsular extension (ECE), nodal
involvement (pN1), and/or positive surgical margins was
recorded, and tumor staging was defined using the 2010
American Joint Committee on Cancer (AJCC) categoriza-
t i o n .A l lb i o p s ya n dp r o s t a t e c t o m yG l e a s o ns c o r e sw e r e
centrally reviewed and determined using a primary and
secondary Gleason grade +/− at e r t i a r yp a t t e r ni nam a n n e r
similar to that outlined in the 2005 International Society
of Urological Pathology (ISUP) consensus recommendations
[20]. This study was approved by the institutional review
board at the Brigham and Women’s Hospital.
2.3. Follow-Up and Determination of PSA Failure. Adjuvant
radiation therapy was not used. Patient follow-up consisted
of a serum PSA measurement and digital rectal examination
every 3 months for the first 2 years, every 6 months for the
next 3 years, and annually thereafter. PSA failure was defined
in accordance with American Urological Association (AUA)
guidelines as a postoperative serum PSA level greater than
0.2ng/mL, confirmed on a second measurement at least one
month later [21].
2.4. Statistical Methods
2.4.1.ComparisonoftheDistributionofClinicalandPathologic
Factors in Men Selected for Bilateral or Unilateral versus
Non-Nerve Sparing Radical Prostatectomy. The distribution
of PSA, PPB, age, clinical tumor category, biopsy and prosta-
tectomy Gleason score, and prostatectomy tumor category
and margin status was compared across men who had bilat-
eral,unilateral,ornon-NSRP.Thedistributionsofthesechar-
acteristics were compared using a Mantel-Haenszel Chi
Squaredmetricforcategoricalfactorsand[22]anonparamet-
ricWilcoxonstatisticforcontinuouscovariates[23](Table 1).
In the case of small sample size, a Fisher’s exact test was
employed [22].
2.4.2. Time to PSA Failure Analyses. A Cox Proportional
Hazards multivariable regression model was used to evaluate
whetherincreasingPSAoruseofUNSorBNSversusnon-NS
RP was associated with the risk of PSA failure after adjusting
for known predictors of PSA failure, including an interaction
term between PPB and PSA in the absence of adjuvant
radiation therapy use [24]. Because PPB was used whereas
PSA level was not used as a selection criterion for NS RP and
becausebothPSAandPPBareassociatedwithtumorvolume,
which may in turn increase the risk of positive surgical
margins and subsequent PSA failure following NS RP, we
included an interaction term in the model between PSA and
PPB. Other variables included in the multivariable model
included age, PSA and PPB (both continuous) at diagnosis,
Gleason Score (8–10 versus 7 versus 6 or less as baseline),
tumorcategory(cT2-3versusT1casbaseline),andtypeofNS
RP (UNS or BNS versus non-NS as baseline). Unadjusted
andadjusted hazardratioswith95%confidenceintervalsand
associated 𝑃 values were calculated for each covariate. A 2-
sided 𝑃 value < 0.05 was considered statistically significant.
SAS version 9.3 was used for all statistical analyses (SAS
Institute, Inc. Cary, NC).
2.4.3. Estimates of PSA Failure. The Kaplan-Meier method
wasusedtoestimatePSAfailure-freesurvivalformenfollow-
ing RP stratified by whether bilateral, unilateral, or non- NS
was employed [7]. Comparison of these Kaplan-Meier esti-
mates was performed using a log rank test [25]. A BonferroniProstate Cancer 3
Table 1: Comparison of the distribution of clinical and pathologic factors in men selected for bilateral or unilateral versus non-nerve sparing
radical prostatectomy.
Clinical factor
Non-nerve sparing
(non-NS)
𝑁=1 9
Unilateral nerve
sparing (UNS)
𝑁 = 151
Bilateral nerve
sparing (BNS)
𝑁 = 187
𝑃 value comparing
non-NS, UNS, and BNS
Median PSA (IQR) (ng/mL) 4.6 [4.0, 10.0] 5.0 [4.0, 6.2] 4.6 [3.5, 6.0] 0.137
Median PPB (IQR) (%) 50.0 [18.2, 70.0] 33.3 [25.0, 50.0] 16.7 [10.0, 25.0] <0.0001
PSA and PPB category
∗
Both > median 8 (10.39%) 50 (64.94%) 19 (24.68%) <0.0001
∗∗
PSA > median
PPB ≤ Median 1 (1.04%) 30 (31.25%) 65 (67.71%) <0.0001
∗∗
PSA ≤ median
PPB > median 5 (6.25%) 49 (61.25%) 26 (32.50%) <0.0001
∗∗
Both ≤ median 5 (4.81%) 22 (21.15%) 77 (74.04%) <0.0001
∗∗
Median age (IQR) (yrs) 60.2 [52.0, 67.2] 61.4 [57.4, 64.9] 57.8 [52.9, 61.9] <0.0001
AJCC clinical tumor category <0.0001
∗∗
1c 16 (84%) 109 (72%) 170 (91%)
2-3 3 (16%) 42 (28%) 17 (9%)
Biopsy Gleason score <0.0001
∗∗
7 or less 11 (58%) 131 (87%) 187 (100%)
8 to 10 8 (42%) 20 (13%) 0 (0%)
AJCC prostatectomy tumor category <0.0001
∗∗
2 12 (63%) 119 (79%) 174 (93%)
3-4 7 (37%) 32 (21%) 13 (7%)
Prostatectomy Gleason score <0.0001
∗∗
7 or less 13 (68%) 129 (85%) 187 (100%)
8–10 6 (32%) 22 (15%) 0 (0%)
Margin status <0.0001
∗∗
Positive 8 (42%) 18 (12%) 10 (5%)
Negative 11 (58%) 133 (88%) 177 (95%)
PSA:prostate-specificantigen;PPB:percentageofpositiveprostatebiopsies;IQR:interquartilerange;AJCC:AmericanJointCommissiononCancer.
∗Overall,
m e d i a nP P B=2 5 % ;o v e r a l l ,m e d i a nP S A=4 . 8n g / m L ;o v e r a l l ,7 %h a dP S A≥ 10ng/mL. ∗∗Fisher exact test 𝑃 value.
correction was applied to adjust for multiple comparisons
(𝑛=3 ), such that a significant 𝑃 value was <0.05/3 or
0.0167 [26]. Point estimates of PSA failure-free survival with
associated 95% confidence intervals were calculated and
reported.
3. Results
3.1. Comparison of the Distribution of Clinical and Pathologic
Factors in Men Selected for Bilateral or Unilateral versus Non-
Nerve Sparing Radical Prostatectomy. As shown in Table 1,
men undergoing BNS compared to UNS and non-NS were
significantly younger and had more favorable disease char-
acteristics including median PPB, clinical tumor category,
biopsy Gleason score, as well as prostatectomy findings of
tumorcategory,Gleasonscore,andmarginstatus(all𝑃values
for trend < 0.0001). However, median PSA was not signifi-
cantlydifferentbetweenmenundergoingBNS,UNS,ornon-
NS, respectively, 4.6ng/mL, 5.0ng/mL, and 4.6ng/mL (𝑃
value for trend = 0.137). Overall, 7% of men in this study had
a PSA of 10ng/mL or more.
As indicated by the distribution of BNS, UNS, non-NS
across PPB and PSA categories, Table 1 also illustrates that
PPB was used as a selection criteria for NS whereas PSA
level was not. Specifically, high PPB (>median of 25%) led
to lower rates of BNS between 25 and 33%, whereas high
PSA(>medianof4.8ng/mL)didnotcorrelatetoincreasedor
decreased use of BNS ranging from a high of 68% when the
PPB was ≤median to a low of 25% when the PPB was greater
thanthemedian.AmongmenwithlowPPB(<median),rates
ofBNSremainedhighat68%and7 4%irrespectiveofwhether
t h eP S Al e v e lw a sg r e a t e rt h a nm e d i a no rl e s st h a nm e d i a n ,
respectively.
3.2. Time to PSA Failure Analysis. After a median follow-
up of 3.96 years (interquartile range 1.92–5.00), 34 out of
357 men sustained PSA failure (9.5%). While increasing PSA
was significantly associated with an increased risk of PSA
failureintheinteractionmodel(adjustedhazardratio(AHR):
1.09 [95% Confidence Interval (CI): 1.03 to 1.16]; 𝑃 = 0.005)
the use of UNS (AHR: 1.24 [95% CI: 0.36 to 4.34]; 𝑃 = 0.73)
or BNS (AHR: 0.41 [95% CI: 0.06–2.59]; 𝑃 = 0.34)v e r s u s
non-NS RP was not.4 Prostate Cancer
Table 2: Univariable and Multivariable hazard ratios for clinical factors from the Cox regression analysis for the risk of PSA-failure.
Clinical factor Number of men Number of events Univariable analysis Multivariable analysis
HR (95% CI) 𝑃 value AHR (95% CI) 𝑃 value
Age at diagnosis (years) 357 34 0.99 (0.95, 1.04) 0.814 0.98 (0.92, 1.05) 0.542
PSA (ng/mL) 357 34 1.09 (1.04, 1.15) 0.001 1.09 (1.03, 1.16) 0.005
PPB (%) 357 34 1.04 (1.02, 1.06) <0.001 1.03 (1.01, 1.05) 0.009
PSA & PPB interaction 357 34 0.999 (0.998, 1.000) 0.177 0.999 (0.998, 1.000) 0.054
Highest Gleason score
62 0 8 2 1 ( R e f ) — 1 ( R e f ) —
7 1 2 1 1 7 1 5 . 2 4( 3 . 5 2 ,6 5 . 9 9 ) <0.001 9.70 (2.17, 43.37) 0.003
8–10 28 15 67.60 (15.45, 295.75) <0.001 25.01 (5.08, 123.14) <0.001
AJCC clinical tumor category
T1c 295 19 1 (Ref) — 1 (Ref) —
T2-3 62 15 3.77 (1.91, 7.42) <0.001 1.49 (0.72, 3.08) 0.283
Type of nerve sparing RP
BNS 187 3 0.043 (0.011, 0.173) <0.001 0.407 (0.064, 2.589) 0.341
UNS 151 25 0.473 (0.193, 1.156) 0.101 1.242 (0.355, 4.342) 0.734
Non-NS 19 6 1 (Ref) — 1 (Ref) —
HR:hazardratio;AHR:adjustedhazardratio;PSA:prostate-specificantigen;PPB:percentageofpositiveprostatebiopsies;AJCC:AmericanJointCommission
on Cancer; RP: radical prostatectomy; BNS: bilateral nerve sparing; UNS: unilateral nerve sparing; Non-NS: non-nerve sparing.
Other factors significantly associated with an increased
risk of PSA failure included increasing PPB (AHR: 1.03 [95%
CI: 1.01 to 1.05]; 𝑃 = 0.009), biopsy Gleason score 7 (AHR:
9.70 [95% CI: 2.17 to 43.37]; 𝑃 = 0.003), and biopsy Gleason
score 8–10 (AHR: 25.01 [95% CI: 5.08 to 123.14]; 𝑃 < 0.001)
compared to 6 or less.
3.3. Estimates of PSA Failure. As shown in Figure 1,t h e
univariable estimates of PSA failure-free survival decreased
significantlyinmenundergoingnon-NSascomparedtoUNS
as compared to BNS (overall log-rank test 𝑃 value < 0.0001).
Specifically, 4-year point estimates of PSA failure-free sur-
vivalformenundergoingBNS,UNS,andnon-NSwere98.7%
(95% CI: 94.9 to 99.7%), 84.4% (95% CI: 75.9 to 90.0%), and
58.0% (95% CI: 27.7 to 79.4%), respectively.
4. Discussion
In this study, we found that men undergoing UNS or
BNS versus non-NS had more favorable prognostic factor
distributions (Table 1) with respect to PPB, Gleason score,
andTcategorybutnotPSAlevel,whichisconsistentwiththe
selection criteria used for NS. This is in turn was reflected in
more favorable PSA outcomes among men undergoing UNS
or BNS versus non-NS RP, as illustrated in Figure 1.H o w ever ,
after adjusting for prognostic factors in the multivariable
model, the use of UNS or BNS as compared to non-NS no
longer predicted for a lower risk of PSA failure (Table 2),
despitethelackofuseofadjuvantradiationtherapy.Together,
these data support that the selection criteria used for NS in
th i ss t ud ya r ee ff ecti v ea n dd on o tp la c em e na tin c r ea sedri s k
of PSA failure.
Nevertheless, some investigators have published that a
PSA < 10ng/mL and no more than one high-grade core
biopsy predicts for ipsilateral organ confined disease at a rate
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Figure 1: PSA failure-free survival following radical prostatectomy,
stratified by whether one, both, or neither nerve was spared.
of 88.5% [27]. Therefore some have advocated for use of
PSA < 15ng/mL in addition to diffusion weighted MRI, PPB,
and T category to select patients for NS RP [28]. Results
in the current study cannot be used to design the optimal
cut-point (i.e., <10 or <15ng/mL), given that 93% of men in
this cohort had a PSA < 10ng/mL. While the results of this
study support the hypothesis that the use of UNS or BNS
did not impact the increased risk of PSA failure conferred by
increasing preoperative PSA level, a prospective assessmentProstate Cancer 5
in which men are randomly assigned to BNS versus non-
NS if their PSA level exceeds a predetermined cut-point and
i fa l lo t h e rc r i t e r i af o rN SR Pu s e di nt h i ss t u d ya r em e t
could be considered to determine the impact of preoperative
PSA level on future risk of PSA failure. Such a study could
ascertain whether the increased risk of PSA failure observed
withincreasingpre-RPPSAlevelisduetolocalpersistenceof
disease that NS may have contributed to or micrometastatic
disease, which NS would have no impact on.
Several points require further discussion. First, the deci-
sion to perform BNS in our study depended only on the PPB
value being low and not on the value of the PSA, as shown in
Table 1. Therefore we included an interaction term between
PPB and PSA in our multivariable model, given that it is
kn o wnth a tin cr ea sin gP P Ba n dPSAa r ebo tha s socia t edwi th
increased tumor volume, risk of positive margins, and subse-
quent PSA failure following NS RP [29–31]. We found that in
the multivariable model, the interaction term between PPB
and PSA approached significance (𝑃 = 0.054)a n dh a dH R<
1, suggesting that these two factors contribute information
regarding the risk of PSA failure interactively. Specifically,
this near-significant interaction in our model between PPB
a n dP S Al e n ts u p p o r tt ot h eh y p o t h e s i st h a ta ni n c r e a s i n g
PSA level led to a higher risk of PSA failure, when PPB was
less than 2/3. The value of 2/3 was determined by using a
mathematicalformulationinvolvingtakingthelogarithmsof
the AHRs corresponding to PPB, PSA, and PPB
∗PSA from
theCoxinteractionmodel.Second,we knowthatnotallPSA
failures lead to clinically significant outcomes such as distant
metastasis (DM) or death from prostate cancer. Specifically,
asthePSADTdecreases,theriskofobservingtheseclinically
significant endpoints increases [32, 33]. Therefore, further
follow-up of the data in this study is needed to ascertain if
the association between increasing pre-RP PSA level and an
increased risk of PSA failure translates to increased risks
of DM and death from prostate cancer. Third, studies have
not found inferior PSA outcomes when minimally invasive
techniques such as robotic or laparoscopic RP as compared
to open RP are performed. [34–36]. Therefore, these data
using open RP should apply to patients undergoing robotic
orlaparoscopicRP. Fourth,themedianPSAinthisstudy was
4.8ng/mL, with only 7% of men having a PSA ≥ 10ng/mL.
Therefore, prospective studies in which men who meet all
requirements for NS as described in this study but have a
PSA in excess of 10ng/mL should be performed in order to
r i g o r o u s l ya s s e s st h ei m p a c to fP S Al e v e la saN Sc r i t e r i o no r
not on future risk of PSA failure.
Despite these considerations, using criteria for NS that
did not include PSA, the use of NS did not increase the risk
of PSA failure in a cohort screened with PSA. Therefore it
appears that while increasing PSA level was associated with
an increased risk of PSA failure, the use of UNS or BNS as
comparedtonon-NSRPwasnotsuggestingthatfactorsother
thanNSwereresponsiblefortheincreasedriskofPSAfailure
in men with high pre-RP PSA levels. Whether the increased
riskofPSAfailureobservedwithincreasingpre-RPPSAlevel
can be reduced by including a predetermined PSA cut-point
to select for non-NS requires additional study.
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